SUBSCRIPTION ONLY Agencies Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk The holding company beat out incumbent WPP for the U.S. account valued at $520 million The logo of the pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on December 23, 2025. (Photo by Kristian Tuxen Ladegaard Berg/NurPhoto via Getty Images) Credit: NurPhoto (Getty) By Christopher Cicchiello --> Omnicom will be the agency-of-record to manage Novo Nordisk’s U.S. media planning and buying, a spokesperson for the Danish pharmaceutical company confirmed to ADWEEK.
Novo Nordisk is known for manufacturing GLP-1 medications Ozempic and Wegovy.
“We look forward to working with the Omnicom team as we continue to scale consumer-focused strategies and connect with patients through emerging channels and technologies, helping bring even greater awareness of our medicines to people living with chronic conditions such as obesity and diabetes,” the spokesperson said.
The global account is valued at $618 million, with the U.S. account valued at $520 million, according to data from COMvergence.
Subscribe and get full access to the news, insights, and expertise that keep industry professionals ahead of the curve.
Christopher Cicchiello is ADWEEK's agencies reporter. Previously, he was on the breaking news assignment desk at NBC News in Washington D.C., where he earned an Emmy nomination for his 2024 election coverage. His byline has appeared in NBC News, TODAY, Quincy News, The Times Union, and The Daily Orange.
By submitting your email, you agree to our Terms of Use and Privacy Policy . You may opt-out anytime by clicking 'unsubscribe' from the newsletter or from your account.
Select ADWEEK as one of your favorite sources and stay up to date on our latest content.